Healis Therapeutics Partners with Mass General for Neuroscience Research

Healis Therapeutics, a company focused on neurotherapeutics, has recently announced its clinical collaboration with General Hospital (MGH) and Harvard Medical School (HMS) affiliates. 

The partnership aims to study the safety and effectiveness of CKDB-501A, a BoNT/A neuromodulator, for treating neuropsychiatric conditions, including but not limited to major depressive disorder (MDD), PTSD, and social anxiety disorder (SAD).

Healis' strategic priority is to develop the research of Dr. Eric Finzi, who has discovered the efficacy of BoNT/A neuromodulators for neuropsychiatric disorders. Dr. Eric Finzi, co-founder of Healis Therapeutics, believes there is a significant need for such treatments among the neuropsychiatric patient population. He is thrilled to work with the world's leading psychiatry researchers and bring deep clinical expertise to Healis Therapeutics' upcoming trial.

Healis Therapeutics' clinical program in BoNT/A for neuropsychiatry has the potential to transform the lives of millions of patients suffering from major depressive disorder globally. Erik Van Widenfelt, Head of Clinical Trials at Healis Therapeutics and a former collaborator of Harvard T Chan School of Public Health and major biopharma companies such as Merck, Roche, Bristol Myers Squibb, Glaxo-Smith Klein, and others, acknowledges that MDD remains a public health challenge worldwide.

Sebastian De Beurs, co-founder of Healis Therapeutics, is thrilled to partner with Mass. General Hospital (MGH) and Harvard Medical School believe they are at the forefront of this field of research.